Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

T R D J Radstake; M Svenson; A M Eijsbouts; F H J van den Hoogen; C Enevold; P L C M van Riel; K Bendtzen

doi:10.1136/ard.2008.092833

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

T R D J Radstake, M Svenson, A M Eijsbouts, F H J van den Hoogen, C Enevold, P L C M van Riel, K Bendtzen

348 Citationer (Scopus)

Abstract

Tumour necrosis factor alpha (TNFalpha) neutralising antibody constructs are increasingly being used to treat rheumatoid arthritis (RA).

Originalsprog	Engelsk
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	68
Udgave nummer	11
Sider (fra-til)	1739-45
Antal sider	7
ISSN	0003-4967
DOI	https://doi.org/10.1136/ard.2008.092833
Status	Udgivet - 1 nov. 2009

Adgang til dokumentet

10.1136/ard.2008.092833

Andre filer og links

Link to publication in Scopus

Citationsformater

Radstake, T. R. D. J., Svenson, M., Eijsbouts, A. M., van den Hoogen, F. H. J., Enevold, C., van Riel, P. L. C. M., & Bendtzen, K. (2009). Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Annals of the Rheumatic Diseases, 68(11), 1739-45. https://doi.org/10.1136/ard.2008.092833

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. / Radstake, T R D J; Svenson, M; Eijsbouts, A M et al.
I: Annals of the Rheumatic Diseases, Bind 68, Nr. 11, 01.11.2009, s. 1739-45.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{ec0e3d0fcb754720b460bd8f2f3c703d,

title = "Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis",

abstract = "Tumour necrosis factor alpha (TNFalpha) neutralising antibody constructs are increasingly being used to treat rheumatoid arthritis (RA).",

author = "Radstake, \{T R D J\} and M Svenson and Eijsbouts, \{A M\} and \{van den Hoogen\}, \{F H J\} and C Enevold and \{van Riel\}, \{P L C M\} and K Bendtzen",

year = "2009",

month = nov,

day = "1",

doi = "10.1136/ard.2008.092833",

language = "English",

volume = "68",

pages = "1739--45",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier BV",

number = "11",

}

TY - JOUR

T1 - Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

AU - Radstake, T R D J

AU - Svenson, M

AU - Eijsbouts, A M

AU - van den Hoogen, F H J

AU - Enevold, C

AU - van Riel, P L C M

AU - Bendtzen, K

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Tumour necrosis factor alpha (TNFalpha) neutralising antibody constructs are increasingly being used to treat rheumatoid arthritis (RA).

AB - Tumour necrosis factor alpha (TNFalpha) neutralising antibody constructs are increasingly being used to treat rheumatoid arthritis (RA).

UR - https://www.scopus.com/pages/publications/70449725246

U2 - 10.1136/ard.2008.092833

DO - 10.1136/ard.2008.092833

M3 - Journal article

C2 - 19019895

SN - 0003-4967

VL - 68

SP - 1739

EP - 1745

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 11

ER -

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater